PeptideWise

Semax vs Selank: Cognitive Peptides Compared

A detailed comparison of Semax and Selank, two Russian-developed nootropic peptides. Covers their distinct cognitive profiles: Semax for stimulating focus and Selank for anxiolytic calm.

Last updated: 2026-03-29

Semax

Evidence Level
Level B
Regulatory Status
Approved AbroadRegistered drug in Russia and Ukraine
Category
Cognitive Enhancement
Administration
Nasal
Onset Time
15-30 minutes
Half-Life
Minutes (rapid metabolism)
Key Mechanism
Semax exerts its effects through several complementary neurological mechanisms: BDNF upregulation: Semax dramatica...

Selank

Evidence Level
Level B
Regulatory Status
Approved AbroadRegistered drug in Russia
Category
Cognitive Enhancement
Administration
Nasal
Onset Time
15-30 minutes
Half-Life
N/A
Key Mechanism
Selank's anxiolytic and cognitive effects appear to arise from several mechanisms: GABA system modulation: Selank ...

Key Differences

Semax and Selank are both synthetic heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and both are registered pharmaceutical drugs in Russia. Despite their shared origin and nasal spray administration route, they have distinctly different pharmacological profiles and cognitive effects.

Core Pharmacology

Semax is derived from the 4-7 fragment of adrenocorticotropic hormone (ACTH) and primarily acts through BDNF upregulation, melanocortin receptor activation, and dopaminergic modulation. Its profile is cognitively activating and stimulating — it enhances focus, memory encoding, and mental energy. Semax interacts with MC3R and MC4R melanocortin receptors in the CNS, which are involved in learning, attention, and stress responses.

Selank is derived from tuftsin, a naturally occurring immunomodulatory tetrapeptide from IgG immunoglobulin. Its primary mechanisms are GABA system modulation, serotonergic effects, and enkephalin system enhancement. Selank produces anxiolytic (anti-anxiety) effects without the sedation or cognitive impairment associated with benzodiazepines. It also upregulates BDNF, but its dominant effect is calming rather than stimulating.

Cognitive Profile

The key distinction is the qualitative character of cognitive enhancement. Semax is stimulating — users and researchers describe increased mental clarity, faster processing, and heightened motivation, similar in character (though milder) to conventional psychostimulants. Selank is anxiolytic — it reduces anxiety and stress while providing a calmer, steadier form of cognitive enhancement focused on emotional regulation and stress resilience.

Regulatory Status

Both peptides carry Level B evidence (human clinical trials completed) and are registered drugs in Russia. Semax is approved for stroke treatment, cognitive impairment, and ADHD-like conditions. Selank is approved for generalized anxiety disorder and as an anxiolytic/nootropic agent. Neither is FDA-approved in the United States.

Combination Use

Semax and Selank are frequently combined for complementary effects: Semax for cognitive activation during demanding tasks and Selank for anxiety management and emotional balance. A common approach is Semax in the morning for focus and Selank in the afternoon or during high-stress periods for calming effects. No controlled studies of the combination exist in humans.

Which Is Better For...?

Semax

Cognitive performance and productivity — Semax provides stimulating focus, enhanced memory encoding, and mental energy through BDNF upregulation and dopaminergic modulation. Best suited for demanding cognitive tasks.

Semax

Neuroprotection and stroke recovery — Semax is clinically used in Russia for ischemic stroke treatment, with published data showing improved neurological outcomes and reduced infarct size.

Selank

Anxiety reduction without sedation — Selank provides anxiolytic effects comparable to benzodiazepines without the sedation, cognitive impairment, or dependence risk. Ideal for anxiety-related cognitive interference.

Selank

Calm, sustained focus under stress — Selank enhances cognitive function while reducing stress-induced impairment, making it suited for high-pressure situations where anxiety would otherwise degrade performance.

Frequently Asked Questions

Can Semax and Selank be used together?
Semax and Selank are commonly combined in the research and nootropic communities for complementary effects. Semax provides cognitive activation and focus, while Selank provides anxiolytic balance. A typical approach is Semax in the morning for productivity and Selank in the afternoon or during stressful periods. Both are administered intranasally and can be used on the same day. No controlled human studies of the combination exist.
Which is better for someone with anxiety who needs to focus?
For individuals where anxiety is the primary barrier to cognitive performance, Selank may be the more appropriate starting point. Its anxiolytic effects can remove the anxiety-driven interference that impairs focus, while still providing mild cognitive enhancement through BDNF upregulation. Semax, being stimulating, can potentially worsen anxiety in sensitive individuals, particularly at higher doses. Some researchers report that starting with Selank and later adding low-dose Semax provides the best balance.
Do Semax and Selank have withdrawal effects?
Neither Semax nor Selank is associated with significant physical withdrawal or dependence based on published Russian clinical data. Selank specifically is noted for its lack of the withdrawal syndrome characteristic of benzodiazepines. Semax does not appear to cause rebound cognitive impairment. Both peptides are typically used in cycled protocols (10-14 day courses with breaks), though continuous use is also described in some protocols.
Are the Russian clinical trials for these peptides reliable?
Russian clinical trials for both Semax and Selank provide meaningful evidence, but they have limitations by Western regulatory standards. Study designs vary in rigor, sample sizes are sometimes modest, and independent replication outside Russia is limited. That said, both peptides have registered drug status in Russia — a level of regulatory validation that most research peptides lack. The BDNF and GABA mechanisms are well-characterized in preclinical studies that meet international standards. Western clinical trials would strengthen confidence significantly.

Read Full Profiles

SemaxSelank